Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vivjoa (oteseconazole) is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Recurrent Vulvovaginal Candidiasis (RVVC) Treatment: Oteseconazole (Vivjoa) significantly reduced the incidence of RVVC, with a pooled odds ratio (OR) of 0.07 (95% CI = 0.05-0.11) through week 48 and an OR of 0.05 (95% CI = 0.03-0.09) through week 24.
• Multidrug-Resistant Candida auris (C. auris) Infections: Oteseconazole, alongside other investigational antifungals, showed significant improvements in survival and reductions in tissue fungal burden in neutropenic animal models of candidemia due to C. auris.
• Oteseconazole was non-significantly associated with developing serious adverse effects during the treatment for recurrent vulvovaginal candidiasis (RVVC) compared to placebo (OR = 0.79; 95% CI = 0.33-1.89; p = 0.60, I² = 0%).
• Safety outcomes for Oteseconazole in the context of Candida auris infections were not explicitly discussed.
• There is no population types or subgroups information available in the reviewed studies.